Consensus Design Therapeutics, Inc.

Equities

DSGN

US25056L1035

Real-time Estimate Cboe BZX Other stock markets 12:17:50 2024-04-29 pm EDT			5-day change	1st Jan Change
3.775 ^USD	-0.13%		-3.50%	+41.66%

Mar. 20	Sector Update: Health Care Stocks Ease Late Afternoon	MT
Mar. 20	Sector Update: Health Care Stocks Down Wednesday Afternoon	MT

Evolution of the average Target Price on Design Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

76b91502efd6840465e95.FPfXgxLoEel6HXpPYrsPthkx_n6VenNRK2nreB2k4N8.J5q52XyxQr80ZzAmFN945VMBskfHIiQ6cQ2aMn7D1pFtvoLwZ4JSnQpKNw~0d343e2393dbc9610560fc3777c0a8df

Analyst Recommendations on Design Therapeutics, Inc.

RBC Cuts Price Target on Design Therapeutics to $4 From $7 Amid Limited Near-Term Clinical Updates, Keeps Sector Perform, Speculative Risk	Nov. 14	MT
Wedbush Trims Design Therapeutics' PT to $5 From $6, Says Waiting for 2024 Strategic Update; Maintains Neutral Rating	Nov. 14	MT
Wedbush Downgrades Design Therapeutics to Neutral From Outperform, Pushes Back DT-216 Launch Timing; Cuts PT to $6 From $19	23-08-15	MT
SVB Downgrades Design Therapeutics to Market Perform From Outperform, Cuts Price Target to $6 From $22	23-08-15	MT
Wedbush Downgrades Design Therapeutics to Neutral From Outperform, Pushes Back DT-216 Launch Timing; Cuts PT to $6 From $19	23-08-15	MT
RBC Downgrades Design Therapeutics to Sector Perform From Outperform, Cuts Price Target to $7 From $23 Amid 'Limited Near-Term Catalysts,' Keeps Speculative Risk	23-08-15	MT
RBC Trims Price Target on Design Therapeutics to $23 From $24, Maintains Outperform Rating, Speculative Risk Qualifier	23-05-10	MT
Wedbush Trims Design Therapeutics' Price Target to $19 From $20, Keeps Outperform Rating	23-05-10	MT
Goldman Sachs Upgrades Design Therapeutics to Neutral From Sell, Price Target is $6	23-05-04	MT
Wedbush Lifts Design Therapeutics' Price Target to $20 From $19, Keeps Outperform Rating	23-03-15	MT
SVB Securities Lowers Price Target on Design Therapeutics to $22 From $30, Maintains Outperform Rating	22-12-09	MT
RBC Cuts Price Target on Design Therapeutics to $24 From $29, Maintains Outperform Rating, Speculative Risk Qualifier	22-12-08	MT
Wedbush Cuts Design Therapeutics' PT to $19 From $26, Pushes Back Expected Market Entry of DT-216 to 2026 After Trial Results; Keeps Outperform Rating	22-12-08	MT
RBC Trims Price Target on Design Therapeutics to $29 From $30, Maintains Outperform, Speculative Risk Rating	22-11-04	MT
Wall Street Set to Open Lower as Mortgage Rates Climb to 16-Year High	22-10-05	MT
US Futures Lower as Mortgage Rates Climb to 16-Year High	22-10-05	MT
Wedbush Adjusts Price Target on Design Therapeutics to $26 From $21, Keeps Outperform Rating	22-08-09	MT
Wedbush Starts Design Therapeutics at Outperform With $21 Price Target	22-06-10	MT
Goldman Sachs Adjusts Design Therapeutics Price Target to $6 From $8, Maintains Sell Rating	22-05-24	MT
SVB Leerink Adjusts Design Therapeutics' Price Target to $30 from $36, Keeps Outperform Rating	22-05-10	MT
Design Therapeutics Initiated by RBC at Outperform, Speculative Risk With $30 Price Target	22-05-02	MT
Goldman Sachs Analyst Starts Design Therapeutics at Sell With $10 Price Target	22-01-19	MT
DESIGN THERAPEUTICS : Goldman Sachs Initiates Design Therapeutics at Neutral Rating With $28 Price Target	21-04-20	MT
DESIGN THERAPEUTICS : Piper Sandler Initiates Design Therapeutics at Overweight Rating With $42 Price Target	21-04-20	MT
DESIGN THERAPEUTICS : SVB Leerink Starts Design Therapeutics at Outperform With $36 Price Target	21-04-20	MT